The overall goal of this proposal is to understand the cellular and molecular factors that regulate dendritic cell activation in response to aeroallergens. Dendritic cells have been shown to control immune responses both in the priming of naive CD4 T cells and in the re-elicitation of effector CD4 T cell responses at the site of antigen entry. Dendritic cells are not only important in CD4 T cell activation but in regulating differentiation of CD4 T cells into Th2 and Th1 cells. In this application, we question how dendritic cells become activated to aeroallergens without apparent microbial sequences and how dendritic cells induce preferential Th2 responses. We hypothesize that the Toll-like receptor signaling in response to inhaled antigen is essential for both Th1 and Th2 priming and that the dose of pathogen associated molecular pattern (PAMP), in this case lipopolysaccharide, influences dendritic cells to become either Th2- or Th1-inducing. Furthermore, we speculate that IL-13 plays an essential role in amplifying Th2 responses to inhaled antigen by sustaining dendritic cell activation. In this way, innate immune signals are required to initiate adaptive immune responses, but once initiated, adaptive immune signals via IL-13 can provide activation signals to maintain Th2 responses. We will test this hypothesis in two specific aims: 1) To determine the mechanism by which low dose lipopolysaccharide induces Th2 priming following inhaled antigen. 2) To determine the role of IL-13 in Th2 priming. Understanding the factors that regulate the initiation of Th2 responses to aeroallergens will shed light on possible environmental factors influencing the dramatic increase in atopic asthma in the past 15 years. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL054450-13
Application #
7191713
Study Section
Lung Biology and Pathology Study Section (LBPA)
Program Officer
Noel, Patricia
Project Start
1994-12-10
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2009-02-28
Support Year
13
Fiscal Year
2007
Total Cost
$442,463
Indirect Cost
Name
Yale University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Albrecht, Melanie; Arnhold, Markus; Lingner, Sandra et al. (2012) IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell priming. PLoS One 7:e45916
Albrecht, Melanie; Chen, Hui-Chen; Preston-Hurlburt, Paula et al. (2011) T(H)17 cells mediate pulmonary collateral priming. J Allergy Clin Immunol 128:168-177.e8
Dokmeci, Elif; Xu, Lan; Robinson, Eve et al. (2011) EBI3 deficiency leads to diminished T helper type 1 and increased T helper type 2 mediated airway inflammation. Immunology 132:559-66
Tan, Anna M; Chen, Hui-Chen; Pochard, Pierre et al. (2010) TLR4 signaling in stromal cells is critical for the initiation of allergic Th2 responses to inhaled antigen. J Immunol 184:3535-44
Dittrich, Anna M; Chen, Hui-Chen; Xu, Lan et al. (2008) A new mechanism for inhalational priming: IL-4 bypasses innate immune signals. J Immunol 181:7307-15
Cook, Donald N; Bottomly, Kim (2007) Innate immune control of pulmonary dendritic cell trafficking. Proc Am Thorac Soc 4:234-9
Piggott, Damani A; Eisenbarth, Stephanie C; Xu, Lan et al. (2005) MyD88-dependent induction of allergic Th2 responses to intranasal antigen. J Clin Invest 115:459-67
Eisenbarth, Stephanie C; Zhadkevich, Alex; Ranney, Patricia et al. (2004) IL-4-dependent Th2 collateral priming to inhaled antigens independent of Toll-like receptor 4 and myeloid differentiation factor 88. J Immunol 172:4527-34
Eisenbarth, Stephanie C; Piggott, Damani A; Huleatt, James W et al. (2002) Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 196:1645-51
Cohn, L; Herrick, C; Niu, N et al. (2001) IL-4 promotes airway eosinophilia by suppressing IFN-gamma production: defining a novel role for IFN-gamma in the regulation of allergic airway inflammation. J Immunol 166:2760-7

Showing the most recent 10 out of 15 publications